Search

Displaying results 301 - 310 of 4650 in total
  1. Drug

    Isavuconazonium

    go.drugbank.com/drugs/DB06636
    ApprovedInvestigational

    [A38834] It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations. … , marketed by Astellas under the brand Cresemba.

  2. Drug

    Fondaparinux

    go.drugbank.com/drugs/DB00569
    ApprovedInvestigational

    The monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII). … Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold.

  3. Drug

    Plasminogen

    go.drugbank.com/drugs/DB16701
    ApprovedInvestigational

    Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as [fibrinolysin] - as part of the fibrinolytic pathway that breaks down fibrin blood clots. … [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with

  4. Drug

    Meradimate

    go.drugbank.com/drugs/DB11096
    Approved

    Meradimate, before known as menthyl anthranilate, is used in a maximal concentration of 5% in different products as a UV filter. … Meradimate is approved by the FDA and Health Canada to be used as an ingredient in sunblocking products.[L1113, L2748]

    Mixtures: Body Armor Sun 'n Bug Block, Aloe Up Medicated Lip Ice Sunscreen SPF 30
  5. Drug

    Migalastat

    go.drugbank.com/drugs/DB05018
    ApprovedInvestigational

    This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and other … Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A).

  6. Drug

    Sufentanil

    go.drugbank.com/drugs/DB00708
    ApprovedInvestigational

    The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018 [L4717]. … Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately [L4718].

  7. Drug

    Mitapivat

    go.drugbank.com/drugs/DB16236
    ApprovedInvestigational

    [A245478] On February 17, 2022, the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, inherited disorder leading

  8. Drug

    Sotorasib

    go.drugbank.com/drugs/DB15569
    ApprovedInvestigational

    [L34288] This mutation makes up >50% of all KRAS mutations.[A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s. … Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.

  9. Drug

    Methylene blue

    go.drugbank.com/drugs/DB09241
    ApprovedInvestigational

    The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. … Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market.

    Mixtures: UR N-C Urinary Antiseptic
  10. Drug

    Magnesium hydroxide

    go.drugbank.com/drugs/DB09104
    ApprovedInvestigational

    Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form.

    Mixtures: Up and Up Antacid Anti Gas, Up and Up Famotidine Complete